Lessons from Alzheimer's Disease (AD) Clinical Trials: Instead of “A-Drug”, AD-D prevention to Avert AD

Author(s): Debomoy K. Lahiri

Journal Name: Current Alzheimer Research

Volume 16 , Issue 4 , 2019

DOI : 10.2174/156720501604190424114752

  Journal Home
Become EABM
Become Reviewer

[1]
Alzforum newsletter March 25, 2019: https://www.alzforum.org/news/research-news/biogeneisai-halt-phase-3-aducanumab-trials
[2]
Hsu D, Marshall GA. Primary and secondary prevention trials in Alzheimer disease: looking back, moving forward. Curr Alzheimer Res 14(4): 426-40. (2017).
[3]
Maloney B, Lahiri DK. Epigenetics of dementia: understanding the disease as a transformation rather than a state. Lancet Neurol 15(7): 760-74. (2016).
[4]
Weinstein G, Preis SR, Beiser AS, Kaess B, Chen TC, Satizabal C, et al. Clinical and environmental correlates of serum BDNF: A descriptive study with plausible implications for AD research. Curr Alzheimer Res 14(7): 722-30. (2017).
[5]
Lauritzen I, Pardossi-Piquard R, Bourgeois A, Bécot A, Checler F. Does intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein trigger early neurotoxicity in Alzheimer’s disease? Curr Alzheimer Res (2019).
[http://dx.doi.org/10.2174/1567205016666190325092841]


promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 4
Year: 2019
Published on: 24 April, 2019
Page: [279 - 280]
Pages: 2
DOI: 10.2174/156720501604190424114752

Article Metrics

PDF: 35
HTML: 8
EPUB: 1
PRC: 1



Related Article(s)

Most Downloaded Article(s)